PhoenixAHoMD

Pediatric Hematology & Oncology • Seattle, WA

Pediatric Hematology & Oncology at Seattle Children's Hospital

Join to view full profile

Dr. Ho is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ho's full profile

Already have an account?

Office
2324 Eastlake Ave E Ste 500
Seattle, WA 98102
Phone+1 206-543-8606

Fax+1 206-987-3946

Education & Training

U Washington Affil Hosps2009
Yale-New Haven Medical CenterResidency, Pediatrics, 2003 - 2006
Yale-New Haven Medical CenterInternship, Pediatrics, 2003 - 2004
Northeast Ohio Medical UniversityClass of 2003

Certifications & Licensure

WA State Medical License 2006 - 2025
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Feb 01
Completed
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL Start of enrollment: 2011 Nov 01
Completed
Phase 1
A Safety Study of SGN-CD33A in AML Patients Start of enrollment: 2013 Jul 01
Completed
Phase 1
Safety Study of SEA-CD40 in Cancer Patients Start of enrollment: 2015 Feb 28
Terminated
Phase 1
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS Start of enrollment: 2016 Feb 01
Terminated
Phase 1, Phase 2
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2016 May 01
Terminated
Phase 3
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia Start of enrollment: 2016 Aug 01
Terminated
Phase 1
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2016 Dec 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

48 citations
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia
Katherine Tarlock, Bill H. Chang, Todd M. Cooper, Thomas G. Gross, Sumit Gupta
Pediatric Blood & Cancer. 2015-06-01
30 citations
High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology...
Phoenix A. Ho, Todd A. Alonzo, Robert B. Gerbing, Jessica A. Pollard, Betsy A. Hirsch
British Journal of Haematology. 2013-09-01
113 citations
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia
Eytan M. Stein, Roland B. Walter, Harry P. Erba, Amir T. Fathi, Anjali S. Advani
Blood. 2018-01-25

Journal Articles

A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML
Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Grant Support

Exploiting WT1 Alterations in Pediatric AMLSt. Baldrick's Foundation2012–2014
Exploiting WT1 Genomic Alterations for Target Identification and Minimal Residual Disease Monitoring in Pediatric AMLAlex's Lemonade Stand Foundation2012–2013
Implications of s-SHIP Expression and SHIP Alterations in AMLNICHD2009–2012
SHIP and WT1 Alterations as Markers of PI3K/Akt Activation in Pediatric AMLMary Claire Satterly Foundation2011
Implications of s-SHIP Expression and SHIP Alterations in AMLAmerican Society of Clinical Oncology2009–2010